# A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors

> **NCT06895928** · PHASE2 · RECRUITING · sponsor: **Shanghai Hengrui Pharmaceutical Co., Ltd.** · enrollment: 400 (estimated)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** SHR-A2102
- **DRUG:** Bevacizumab Injection
- **DRUG:** Adebelimab Injection
- **DRUG:** Ametinib Mesylate Tablets
- **DRUG:** Osimertinib Mesylate Tablets

## Key facts

- **NCT ID:** NCT06895928
- **Lead sponsor:** Shanghai Hengrui Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-28
- **Primary completion:** 2028-12
- **Final completion:** 2028-12
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2025-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06895928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06895928, "A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06895928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*